Jefferies analyst Brian Tanquilut has maintained their bullish stance on MCK stock, giving a Buy rating on October 6.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brian Tanquilut has given his Buy rating due to a combination of factors that highlight McKesson’s strong growth potential and strategic initiatives. The company’s recent investor day revealed an increased long-term EPS growth outlook of 13-16%, which is supported by the simplification of its reporting segments. This strategic move enhances visibility into McKesson’s business lines and makes the stock attractive at its current valuation.
Additionally, the planned tax-free separation of the Medical segment is expected to streamline McKesson’s focus on higher-growth, synergistic segments. Although there are risks associated with Part B drug pricing and GLP-1 prior authorizations, these are considered manageable and are outweighed by the company’s broader momentum. The consistent execution and underlying growth evidenced by the new long-range plan justify a more robust valuation multiple, leading to the reaffirmation of the Buy rating and an increased price target of $900.
In another report released on October 6, Leerink Partners also maintained a Buy rating on the stock with a $0.00 price target.